Literature DB >> 315413

Carbohydrate of the factor VIII/von Willebrand factor in von Willebrand's disease.

T S Zimmerman, R Voss, T S Edgington.   

Abstract

We have examined the plasma Factor VIII/von Willebrand factor (FVIII/vWF) molecule from 16 patients with von Willebrand's disease, and have found no evidence of a significant decrease of carbohydrate content in 15 of these patients. FVIII/vWF was isolated by preparative counter immunoelectrophoresis directly from plasma using antibody to Factor VIII-related antigen, reduced in sodium dodecyl sulfate in the presence of urea, and electrophoresed in 5% polyacrylamide gels to separate the FVIII/vWF subunit from other proteins. Duplicate gels were stained by either the periodic acid-Schiff (PAS) reaction or by Coomassie Brilliant Blue G250. The ratio of Coomassie: PAS was determined by spectrophotometric scanning of the gels. Transferrin was used as an internal reference standard. The ratio for 23 normal individuals was 2.4+/-0.38 and the observed range was 1.8-3.8. 15 patients with von Willebrand's disease fell within this range. One patient independently reported as having decreased FVIII/vWF carbohydrate was also studied by this technique. A ratio of 6.8 was found, indicative of decreased, though not absent, carbohydrate. Cold insoluble globulin did not represent a significant contaminant in these analyses. 11 of the von Willebrand's disease patients with normal FVIII/vWF carbohydrate had abnormal crossed immunoelectrophoretic patterns characterized by absence of the less anodic forms of Factor VIII-related antigen. Four patients had normal patterns. These studies indicate that an absence or decrease of PAS reactive FVIII/vWF carbohydrate is not a consistent abnormality in von Willebrand's disease.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 315413      PMCID: PMC371276          DOI: 10.1172/JCI109585

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  14 in total

1.  Binding of soluble form of fibroblast surface protein, fibronectin, to collagen.

Authors:  E Engvall; E Ruoslahti
Journal:  Int J Cancer       Date:  1977-07-15       Impact factor: 7.396

2.  Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein.

Authors:  J M Sodetz; S V Pizzo; P A McKee
Journal:  J Biol Chem       Date:  1977-08-10       Impact factor: 5.157

3.  von Willebrand's disease antigen II. A new plasma and platelet antigen deficient in severe von Willebrand's disease.

Authors:  R R Montgomery; T S Zimmerman
Journal:  J Clin Invest       Date:  1978-06       Impact factor: 14.808

4.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

5.  A high resolution PAS stain for polyacrylamide gel electrophoresis.

Authors:  R A Kapitany; E J Zebrowski
Journal:  Anal Biochem       Date:  1973-12       Impact factor: 3.365

6.  Factor VIII/von Willebrand factor protein. Galactose a cryptic determinant of von Willebrand factor activity.

Authors:  H R Gralnick
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

7.  Von Willebrand's disease: combined qualitative and quantitative abnormalities.

Authors:  H R Gralnick; Y Sultan; B S Coller
Journal:  N Engl J Med       Date:  1977-05-05       Impact factor: 91.245

8.  Carbohydrate on human factor VIII/von Willebrand factor. Impairment of function by removal of specific galactose residues.

Authors:  J M Sodetz; J C Paulson; S V Pizzo; P A McKee
Journal:  J Biol Chem       Date:  1978-10-25       Impact factor: 5.157

9.  Active release of human platelet factor VIII-related antigen by adenosine diphosphate, collagen, and thrombin.

Authors:  J Koutts; P N Walsh; E F Plow; J W Fenton; B N Bouma; T S Zimmerman
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

10.  Heterogeneity of human factor VIII. I. Characterization of factor VIII present in the supernatant of cryoprecipitate.

Authors:  J Over; B N Bouma; J A van Mourik; J J Sixma; R Vlooswijk; I Bakker-Woudenberg
Journal:  J Lab Clin Med       Date:  1978-01
View more
  2 in total

1.  Carbohydrate moiety of von Willebrand factor is not necessary for maintaining multimeric structure and ristocetin cofactor activity but protects from proteolytic degradation.

Authors:  A B Federici; J H Elder; L De Marco; Z M Ruggeri; T S Zimmerman
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

2.  Properties of human asialo-factor VIII. A ristocetin-independent platelet-aggregating agent.

Authors:  L De Marco; S S Shapiro
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.